Hannover Medical School, Hannover, Germany.
Expert Rev Gastroenterol Hepatol. 2010 Jun;4(3):345-53. doi: 10.1586/egh.10.18.
Hepatocellular carcinoma (HCC) represents the third most common cause of cancer-related death worldwide and efficient treatment options are urgently needed. Based on its pathogenesis, in addition to a number of correlative studies, immunotherapy represents a potential therapeutic option for patients with HCC. However, tumors have also evolved numerous immune escape mechanisms, including the generation of cells with immune suppressor functions, such as Tregs and myeloid-derived suppressor cells. It has been shown that these suppressor cells mask tumor-specific immune responses in patients with HCC. Different immunotherapeutic approaches including peptide- and dendritic cell-based therapies have demonstrated promising results in patients with HCC. However, we propose that any of these immunotherapeutic approaches needs to be combined with a therapy specifically targeting suppressor cells in HCC.
肝细胞癌 (HCC) 是全球癌症相关死亡的第三大常见原因，迫切需要有效的治疗方法。基于其发病机制，除了一些相关研究外，免疫疗法也代表了 HCC 患者的一种潜在治疗选择。然而，肿瘤也进化出了许多免疫逃逸机制，包括产生具有免疫抑制功能的细胞，如 Tregs 和髓源性抑制细胞。已经表明，这些抑制细胞掩盖了 HCC 患者的肿瘤特异性免疫反应。不同的免疫治疗方法，包括基于肽和树突状细胞的治疗方法，已在 HCC 患者中显示出有前途的结果。然而，我们认为任何这些免疫治疗方法都需要与专门针对 HCC 抑制细胞的治疗方法相结合。
